CHRNA7 and neoplasm: As a result, paclitaxel-loaded ImI-PMs exhibited remarkable tumor-targeting effectiveness and enhanced antitumor efficacy in MCF-7 tumor-bearing nu/nu mice overexpressing α7 nAChR (Figure 6) [30].